-
Tytuł:
-
GDF15: an emerging modulator of immunity and a strategy in COVID-19 in association with iron metabolism.
-
Autorzy:
-
Rochette L; Pathophysiology and Epidemiology of Cerebro-Cardiovascular Diseases Research Unit (PEC2, EA 7460), University of Burgundy and Franche-Comté, UFR des Sciences de Santé, 21079 Dijon, France. Electronic address: .
Zeller M; Pathophysiology and Epidemiology of Cerebro-Cardiovascular Diseases Research Unit (PEC2, EA 7460), University of Burgundy and Franche-Comté, UFR des Sciences de Santé, 21079 Dijon, France.
Cottin Y; Cardiology Unit, Dijon Bourgogne University Hospital, 21000 Dijon, France.
Vergely C; Pathophysiology and Epidemiology of Cerebro-Cardiovascular Diseases Research Unit (PEC2, EA 7460), University of Burgundy and Franche-Comté, UFR des Sciences de Santé, 21079 Dijon, France.
-
Źródło:
-
Trends in endocrinology and metabolism: TEM [Trends Endocrinol Metab] 2021 Nov; Vol. 32 (11), pp. 875-889. Date of Electronic Publication: 2021 Sep 08.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't; Review
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: New York : Elsevier Science Pub. Co., [c1989-
-
MeSH Terms:
-
COVID-19/*immunology
Cytokine Release Syndrome/*immunology
Endothelium, Vascular/*immunology
Growth Differentiation Factor 15/*immunology
Iron/*metabolism
Apoptosis/immunology ; COVID-19/metabolism ; Cytokine Release Syndrome/metabolism ; Endothelium, Vascular/metabolism ; Endothelium, Vascular/physiopathology ; Glial Cell Line-Derived Neurotrophic Factor Receptors/immunology ; Glial Cell Line-Derived Neurotrophic Factor Receptors/metabolism ; Growth Differentiation Factor 15/metabolism ; Humans ; Immunologic Factors/therapeutic use ; Oxidative Stress/immunology ; Prognosis ; Pyroptosis/immunology ; SARS-CoV-2 ; COVID-19 Drug Treatment
-
References:
-
J Mol Cell Biol. 2021 Mar 10;12(12):916-932. (PMID: 33295606)
Mol Metab. 2018 Mar;9:187-191. (PMID: 29398617)
Front Pharmacol. 2021 Mar 10;12:625678. (PMID: 33776767)
Sci Rep. 2017 Dec 8;7(1):17238. (PMID: 29222479)
Cardiovasc Pathol. 2021 Sep-Oct;54:107361. (PMID: 34174415)
Lancet. 2020 Feb 15;395(10223):514-523. (PMID: 31986261)
Circulation. 2020 Dec;142(22):2128-2137. (PMID: 33058695)
iScience. 2020 Oct 23;23(10):101642. (PMID: 33043282)
J Biol Chem. 2021 Jan-Jun;296:100135. (PMID: 33268377)
Aging (Albany NY). 2019 Nov 9;11(21):9234-9263. (PMID: 31707363)
Lancet. 2020 Feb 22;395(10224):565-574. (PMID: 32007145)
Trends Endocrinol Metab. 2018 Feb;29(2):74-85. (PMID: 29249571)
Cell. 2017 Jun 1;169(6):1000-1011. (PMID: 28575665)
Front Med (Lausanne). 2020 Dec 03;7:594137. (PMID: 33344478)
Front Immunol. 2020 May 19;11:951. (PMID: 32508832)
Geriatr Gerontol Int. 2016 Mar;16 Suppl 1:17-29. (PMID: 27018280)
Cell Death Dis. 2018 May 3;9(5):506. (PMID: 29724997)
Circ Res. 2019 Apr 12;124(8):1166-1168. (PMID: 30973815)
Physiol Rev. 2018 Jan 1;98(1):505-553. (PMID: 29351514)
Arthritis Rheumatol. 2020 Jul;72(7):1059-1063. (PMID: 32293098)
Eur Urol. 2020 Aug;78(2):296-298. (PMID: 32418620)
Front Immunol. 2021 Jun 11;12:649122. (PMID: 34177896)
Scand J Immunol. 2021 Jun;93(6):e13024. (PMID: 33523532)
Pharmacol Ther. 2015 Dec;156:26-33. (PMID: 26523637)
Protein J. 2020 Dec;39(6):644-656. (PMID: 33106987)
Pharmacol Ther. 2013 Dec;140(3):239-57. (PMID: 23859953)
Cell Rep. 2020 Oct 13;33(2):108254. (PMID: 33007239)
JAMA Cardiol. 2020 Jul 1;5(7):811-818. (PMID: 32219356)
Trends Endocrinol Metab. 2020 Dec;31(12):939-951. (PMID: 33172749)
Lancet. 2020 May 2;395(10234):1417-1418. (PMID: 32325026)
N Engl J Med. 2021 Jan 21;384(3):229-237. (PMID: 33113295)
J Leukoc Biol. 2020 Jul;108(1):17-41. (PMID: 32534467)
Int J Mol Sci. 2020 Jul 21;21(14):. (PMID: 32708334)
J Biosci. 2020;45:. (PMID: 33184246)
Eur Heart J. 2020 Nov 1;41(41):4037-4046. (PMID: 32984892)
Ageing Res Rev. 2020 Dec;64:101201. (PMID: 33157320)
Lancet. 2020 May 2;395(10234):1407-1409. (PMID: 32278362)
Front Immunol. 2020 Oct 06;11:581338. (PMID: 33123167)
Cell. 2019 Aug 22;178(5):1231-1244.e11. (PMID: 31402172)
Pharmacol Ther. 2015 Feb;146:35-52. (PMID: 25205158)
Front Pharmacol. 2021 Feb 12;11:585331. (PMID: 33746739)
Trends Pharmacol Sci. 2020 Sep;41(9):598-610. (PMID: 32711925)
Pharmacol Res. 2020 Sep;159:104919. (PMID: 32464324)
Cytokine Growth Factor Rev. 2013 Aug;24(4):373-84. (PMID: 23787157)
Am J Physiol Heart Circ Physiol. 2013 Mar 1;304(5):H709-18. (PMID: 23262134)
Avicenna J Med. 2021 Jan 05;11(1):20-26. (PMID: 33520785)
Nat Med. 2017 Oct;23(10):1215-1219. (PMID: 28846098)
Free Radic Biol Med. 2021 Aug 20;172:688-698. (PMID: 34186206)
Exp Hematol. 2017 Aug;52:24-31. (PMID: 28501597)
Front Immunol. 2020 Oct 23;11:582102. (PMID: 33193390)
Cell Immunol. 2020 Dec;358:104240. (PMID: 33137649)
Pharmaceuticals (Basel). 2021 May 28;14(6):. (PMID: 34071185)
Front Immunol. 2020 May 12;11:915. (PMID: 32477368)
Front Mol Biosci. 2020 Nov 17;7:606393. (PMID: 33282914)
Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1068-75. (PMID: 18375743)
Cytokine Growth Factor Rev. 2021 Feb;57:11-18. (PMID: 33317942)
Nat Rev Immunol. 2020 Jul;20(7):389-391. (PMID: 32439870)
Mediators Inflamm. 2020 Oct 21;2020:5657864. (PMID: 33144847)
Appl Immunohistochem Mol Morphol. 2021 Jan;29(1):5-12. (PMID: 33086222)
Nature. 2020 Dec;588(7838):466-472. (PMID: 32971526)
Biochem Biophys Res Commun. 2020 May 28;526(2):293-299. (PMID: 32209255)
J Med Virol. 2020 Apr;92(4):418-423. (PMID: 31967327)
Nat Rev Microbiol. 2019 Mar;17(3):181-192. (PMID: 30531947)
Front Immunol. 2020 Sep 24;11:558898. (PMID: 33072097)
Science. 2020 Mar 27;367(6485):1444-1448. (PMID: 32132184)
Front Immunol. 2020 Sep 25;11:558341. (PMID: 33072096)
Biophys Chem. 2020 Sep;264:106420. (PMID: 32622243)
Trends Immunol. 2011 Aug;32(8):380-7. (PMID: 21752713)
Am J Respir Crit Care Med. 2021 May 1;203(9):1149-1157. (PMID: 33080140)
Biochem Biophys Res Commun. 2020 May 28;526(2):439-446. (PMID: 32228886)
Trends Endocrinol Metab. 2020 Dec;31(12):893-904. (PMID: 33172748)
Pharmacol Res. 2020 Jul;157:104859. (PMID: 32360480)
Oxid Med Cell Longev. 2020 Jan 27;2020:6372935. (PMID: 32089774)
Mediators Inflamm. 2017;2017:9398401. (PMID: 28798540)
J Pathol. 2020 May;251(1):49-62. (PMID: 32083318)
Int J Mol Sci. 2020 Jul 13;21(14):. (PMID: 32668803)
Mol Nutr Food Res. 2014 Aug;58(8):1721-38. (PMID: 24888568)
Cytokine. 2021 Jan;137:155324. (PMID: 33032108)
Nat Rev Endocrinol. 2018 Oct;14(10):576-590. (PMID: 30046148)
EBioMedicine. 2021 May;67:103382. (PMID: 34000623)
J Immunother Cancer. 2021 May;9(5):. (PMID: 33986127)
Nat Med. 2017 Oct;23(10):1150-1157. (PMID: 28846097)
Autoimmun Rev. 2020 Jun;19(6):102538. (PMID: 32268212)
Cell. 2021 Jan 7;184(1):149-168.e17. (PMID: 33278357)
Cytokine. 2019 Mar;115:13-23. (PMID: 30616034)
Nat Med. 2020 May;26(5):681-687. (PMID: 32327758)
Nat Rev Cardiol. 2020 Sep;17(9):543-558. (PMID: 32690910)
Life Sci Alliance. 2020 Jul 23;3(9):. (PMID: 32703818)
Trends Pharmacol Sci. 2020 Nov;41(11):815-829. (PMID: 32829936)
Nature. 2020 Mar;579(7798):265-269. (PMID: 32015508)
-
Contributed Indexing:
-
Keywords: COVID-19; GDF15; iron; metabolism; therapeutic
-
Substance Nomenclature:
-
0 (GDF15 protein, human)
0 (GFRA1 protein, human)
0 (Glial Cell Line-Derived Neurotrophic Factor Receptors)
0 (Growth Differentiation Factor 15)
0 (Immunologic Factors)
E1UOL152H7 (Iron)
-
Entry Date(s):
-
Date Created: 20211001 Date Completed: 20211022 Latest Revision: 20221221
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC8423996
-
DOI:
-
10.1016/j.tem.2021.08.011
-
PMID:
-
34593305
-
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic of respiratory and cardiovascular diseases, known as coronavirus disease 2019 (COVID-19). SARS-CoV-2 encodes the structural proteins spike (S), envelope (E), membrane (M), and nucleocapsid (N). The receptor-binding domain on the surface subunit S1 is responsible for attachment of the virus to angiotensin (Ang)-converting enzyme 2 (ACE2), which is highly expressed in host cells. The cytokine storm observed in patients with COVID-19 contributes to the endothelial vascular dysfunction, which can lead to acute respiratory distress syndrome, multiorgan failure, alteration in iron homeostasis, and death. Growth and differentiation factor 15 (GDF15), which belongs to the transforming growth factor-β (TGF-β) superfamily of proteins, has a pivotal role in the development and progression of diseases because of its role as a metabolic regulator. In COVID-19, GDF15 activity increases in response to tissue damage. GDF15 appears to be a strong predictor of poor outcomes in patients critically ill with COVID-19 and acts as an 'inflammation-induced central mediator of tissue tolerance' via its metabolic properties. In this review, we examine the potential properties of GDF15 as an emerging modulator of immunity in COVID-19 in association with iron metabolism. The virus life cycle in host cell provides potential targets for drug therapy.
Competing Interests: Declaration of interests The authors declare that there are no conflicts of interest.
(Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)